1-[(1-ピロリジニルカルボニル)メチル]-4-[1-オキソ-3-(3,4,5-トリメトキシフェニル)-2-プロペニル]ピペラジン

1-[(1-ピロリジニルカルボニル)メチル]-4-[1-オキソ-3-(3,4,5-トリメトキシフェニル)-2-プロペニル]ピペラジン 化学特性,用途語,生産方法

• 使用

  Cinepazide is an injection in the treatment of acute myocardial infarction and its effect on serum inflammatory factors.

• 世界保健機関（WHO）

  Cinepazide, a vasodilating agent, was first introduced into medicine in 1974. It is used in the treatment of peripheral and cerebral vascular disorders. Following reports of blood dyscrasias, including agranulocytosis and thrombocytopenia, associated with the use of the drug, the Spanish Committee on Drug Surveillance has recommended its withdrawal. In other countries, the approved product information of preparations containing cinepazide has been amended to include a relevant warning on these adverse effects.

1-[(1-ピロリジニルカルボニル)メチル]-4-[1-オキソ-3-(3,4,5-トリメトキシフェニル)-2-プロペニル]ピペラジン 上流と下流の製品情報

1-[(1-ピロリジニルカルボニル)メチル]-4-[1-オキソ-3-(3,4,5-トリメトキシフェニル)-2-プロペニル]ピペラジン 生産企業

Global(60)Suppliers

23887-46-9, 1-[(1-ピロリジニルカルボニル)メチル]-4-[1-オキソ-3-(3,4,5-トリメトキシフェニル)-2-プロペニル]ピペラジン キーワード